Like Ozempic, Wegovy aims to reduce the risk of future health complications, including heart disease
Because it shows consistent signaling behavior in muscle, connective tissue, vascular, and gut models
The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans
As Fillit noted, GLP-1 drugs would be very good candidates to be delivered in combination with an anti-amyloid drug like Eisai and Biogens recently approved Leqembi (lecanemab) or Lillys investigational donanemab, because there is no overlap in the mechanism of action
As we age, NAD + levels decline leading to slower metabolism, weight gain, fatigue, and other signs of aging